文献速递炎症性肠病

克罗恩病持续缓解患者停用英夫利西单抗后7年结局

Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-10-07

对STORI研究中115例联用抗代谢药维持缓解的克罗恩病患者进行回顾性分析,最终分析102例,中位随访7年。停用英夫利西单抗7年后21%未重启生物制剂且无重大并发症,70.2%的患者降阶梯策略未失败,18.5%发生重大并发症。

要点

  • 停用英夫利西单抗7年后,21%患者未重启生物制剂且无重大并发症。
  • 70.2%患者降阶梯策略未失败(无重大并发症且重启英夫利西单抗未失败)。
  • 上消化道病变、白细胞≥5.0×10^9/L、血红蛋白≤12.5 g/dL与重大并发症独立相关。

核心结论

  • 在STORI队列7年长期随访中,约五分之一患者停用英夫利西单抗后未重启生物制剂且未发生重大并发症。
  • 70%患者降阶梯策略未失败(无重大并发症且重启英夫利西单抗未失败)。

研究设计与样本

  • 对STORI研究115例患者的回顾性分析,该研究于2006年3月至2009年12月在法国和比利时的20个中心开展。
  • STORI队列为前瞻性分析,评估临床缓解且维持抗代谢药治疗的患者停用英夫利西单抗维持治疗后复发风险及相关因素。
  • 最终分析纳入102例患者(来自20个中心中的19个),中位随访7年。

主要发现

  • 停用英夫利西单抗7年后,21%患者未重启英夫利西单抗或其他生物制剂且无重大并发症(95%CI 13.1-30.3)。
  • 重启英夫利西单抗的患者中,重启后6年治疗失败率为30.1%(95%CI 18.5-42.5)。
  • 停用英夫利西单抗7年后,18.5%患者发生重大并发症(95%CI 10.2-26.8),70.2%患者降阶梯策略未失败(95%CI 60.2-80.1)。

关键数值与推荐

  • 与重大并发症独立相关的因素为:停用英夫利西单抗时上消化道病变、白细胞计数≥5.0×10^9/L、血红蛋白≤12.5 g/dL。
  • 具有至少2个上述因素的患者,停用英夫利西单抗后7年内重大并发症风险超过40%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about long-term outcomes of patients with Crohn's disease (CD) after infliximab withdrawal. We aimed to describe the long-term outcomes of patients with CD in clinical remission after infliximab treatment was withdrawn. METHODS: We performed a retrospective analysis of data from the 115 patients included in the infliximab discontinuation in patients with CD in stable remission on combined therapy with antimetabolites (STORI) study, performed at 20 centers in France and Belgium from March 2006 through December 2009. The STORI cohort was a prospective analysis of risk and factors associated with relapse following withdrawal of maintenance therapy with infliximab, maintained on antimetabolites, while in clinical remission. We collected data from the end of the study until the last available follow-up examination on patient surgeries, new complex perianal lesions (indicating major complications), and need for and outcomes of restarting therapy with infliximab or another biologic agent. The de-escalation strategy was considered to have failed when a major complication or infliximab restart failure occurred. RESULTS: Of the 115 patients initially included, data from 102 patients (from 19 of the 20 study centers) were included in the final analysis. The median follow-up time was 7 years. Twenty-one percent of the patients did not restart treatment with infliximab or another biologic agent and did not have a major complication 7 years after infliximab withdrawal (95% CI, 13.1-30.3). Among patients who restarted infliximab, treatment failed for 30.1% 6 years after restarting (95% CI, 18.5-42.5). Overall, at 7 years after stopping infliximab therapy, major complications occurred in 18.5% of patients (95% CI, 10.2-26.8) whereas 70.2% of patients had no failure of the de-escalation strategy (95% CI, 60.2-80.1). Factors independently associated with major complications were upper-gastrointestinal location of disease, white blood cell count ≥ 5.0 × 109/L, and hemoglobin level ≤12.5 g/dL at the time of infliximab withdrawal. Patients with at least 2 of these factors had a more than 40% risk of major complication in the 7 years following infliximab withdrawal. CONCLUSIONS: In a long-term follow-up of the STORI cohort (7 years) one fifth of the patients did not restart infliximab or another biologic agent and did not develop major complications. Seventy percent of patients had no failure of the de-escalation strategy (no major complication and no failure of infliximab restart).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Reenaers C, Mary JY, Nachury M, et al. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. Clin Gastroenterol Hepatol. 2017. PMID: 28993262. doi:10.1016/j.cgh.2017.09.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。